2023-12-19 07:26:41 ET
DENVER, Colo., Dec 19, 2023 ( www.247marketnews.com )- Gilead Sciences, Inc. (NASDAQ: GILD) and Compugen Ltd. (NASDAQ: CGEN) jointly announced, this morning, that they signed an exclusive license agreement for its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. Gilead will make $60 million upfront payment and $30 Million in near term milestone payments, with a total deal value of up to $848 million.
Compugen is trading at $1.07, up $0.34 (+46.58%), on 586K shares traded.
Its 52-week range is $0.53 to $1.4897. This may be on its way to a new 52-week high.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock …
The post Better to Check out This High-Flier appeared first on 24/7 Market News .
For further details see:
Better to Check out This High-Flier